No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E, Hata T, Yokota KI, Chiwata M, Kamijo R, Hashimoto M, Taguchi M, Horai M, Matsuo M, Matsuo E, Takasaki Y, Kawaguchi Y, Itonaga H, Sato S, Ando K, Sawayama Y, Taguchi J, Imaizumi Y, Tsushima H, Jo T, Yoshida S, Moriuchi Y, Miyazaki Y.
Toriyama E, et al. Among authors: miyazaki y.
Cancer Sci. 2020 Dec;111(12):4490-4499. doi: 10.1111/cas.14653. Epub 2020 Oct 23.
Cancer Sci. 2020.
PMID: 32939867
Free PMC article.